All Stories

  1. Bile acid receptor in GtoPdb v.2025.3
  2. Chemerin receptors in GtoPdb v.2025.3
  3. Ghrelin receptor in GtoPdb v.2025.3
  4. Succinate receptor in GtoPdb v.2025.3
  5. Trace amine receptor in GtoPdb v.2025.3
  6. Apelin receptor in GtoPdb v.2025.3
  7. Endothelin receptors in GtoPdb v.2025.3
  8. Short communications: Endothelin-1 in cardiac allograft vasculopathy
  9. Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study
  10. Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein
  11. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
  12. Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue
  13. Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor
  14. Targeting the apelin system for the treatment of cardiovascular diseases
  15. Current and future strategies for targeting the endothelin pathway in cardiovascular disease
  16. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  17. Urotensin receptor in GtoPdb v.2023.1
  18. Trace amine receptor in GtoPdb v.2023.1
  19. Thyrotropin-releasing hormone receptors in GtoPdb v.2023.1
  20. Class A Orphans in GtoPdb v.2023.1
  21. Motilin receptor in GtoPdb v.2023.1
  22. Neuropeptide W/neuropeptide B receptors in GtoPdb v.2023.1
  23. Endothelin receptors in GtoPdb v.2023.1
  24. Kisspeptin receptor in GtoPdb v.2023.1
  25. Succinate receptor in GtoPdb v.2023.1
  26. Apelin receptor in GtoPdb v.2023.1
  27. Bile acid receptor in GtoPdb v.2023.1
  28. QRFP receptor in GtoPdb v.2023.1
  29. Ghrelin receptor in GtoPdb v.2023.1
  30. Chemerin receptors in GtoPdb v.2023.1
  31. Oxoglutarate receptor in GtoPdb v.2023.1
  32. Class A Orphans in GtoPdb v.2022.3
  33. Trans-myocardial Extraction of Endothelin-1 Correlates with Increased Microcirculatory Resistance following Percutaneous Coronary Intervention
  34. In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA
  35. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials
  36. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  37. Class A Orphans in GtoPdb v.2021.3
  38. Urotensin receptor in GtoPdb v.2021.3
  39. Succinate receptor in GtoPdb v.2021.3
  40. Ghrelin receptor in GtoPdb v.2021.3
  41. Chemerin receptors in GtoPdb v.2021.3
  42. The therapeutic potential of apelin in kidney disease
  43. Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
  44. Motilin receptor in GtoPdb v.2021.2
  45. Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection
  46. Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database
  47. Motilin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  48. Kisspeptin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  49. Genes Encoding ACE2, TMPRSS2 and Related Proteins Mediating SARS-CoV-2 Viral Entry are Upregulated with Age in Human Cardiomyocytes
  50. A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
  51. Advances in therapeutic peptides targeting G protein-coupled receptors
  52. Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  53. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  54. Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor
  55. QRFP receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  56. Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  57. Bile acid receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  58. Apelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  59. Oxoglutarate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  60. Chemerin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  61. Ghrelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  62. Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  63. Kisspeptin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  64. Motilin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  65. Neuropeptide W/neuropeptide B receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  66. Succinate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  67. Thyrotropin-releasing hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  68. Trace amine receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  69. Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  70. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand
  71. International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function
  72. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
  73. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  74. Pharmacological targeting of apelin impairs glioblastoma growth
  75. Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [ 18 F]FDG PET Imaging
  76. Vascular Imaging With 18 F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia
  77. 18 F-Fluoride and 18 F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic StrokeCLINICAL PERSPECTIVE
  78. [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13
  79. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial HypertensionClinical Perspective
  80. OUP accepted manuscript
  81. Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal RemodelingNovelty and Significance
  82. Chemerin Elicits Potent Constrictor Actions via Chemokine‐Like Receptor 1 (CMKLR1), not G‐Protein‐Coupled Receptor 1 (GPR1), in Human and Rat Vasculature
  83. Cardiac action of the first G protein biased small molecule apelin agonist
  84. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension
  85. The endothelin hormones, structure and function
  86. The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells
  87. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  88. The Concise Guide to PHARMACOLOGY 2015/16: Overview
  89. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
  90. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system
  91. Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography
  92. LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal
  93. Endothelin Receptors and Their Antagonists
  94. Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist
  95. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12
  96. Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis
  97. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
  98. In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer 18 F-FEDAA1106
  99. Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta
  100. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro
  101. The Concise Guide to PHARMACOLOGY 2013/14: Overview
  102. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
  103. Evolving pharmacology of orphan GPCRs: IUPHAR Commentary
  104. No evidence for a local renin-angiotensin system in liver mitochondria
  105. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension
  106. Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors
  107. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
  108. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer
  109. Themed section: endothelin
  110. IUPHAR-DB: updated database content and new features
  111. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
  112. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice
  113. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways
  114. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues
  115. The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
  116. GuideToPharmacology.org - an update
  117. Cellular Localization of Receptors Using Antibodies Visualized by Light and Dual Labeling Confocal Microscopy
  118. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  119. How to Use the IUPHAR Receptor Database to Navigate Pharmacological Data
  120. Quantitative Phosphor Imaging Autoradiography of Radioligands for Positron Emission Tomography
  121. Radioligand Binding Assays and Their Analysis
  122. Receptor Binding Techniques
  123. Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor
  124. Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature
  125. Discovery of a Competitive Apelin Receptor (APJ) Antagonist
  126. Chemokine receptor CCR5: from AIDS to atherosclerosis
  127. Pharmacology of Renal Endothelin Receptors
  128. International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function
  129. Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation
  130. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function
  131. Endothelial cell-specific ETBreceptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1This article is one of a selection of papers published in the two-part special issue entitled 20 Years o...
  132. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis
  133. Introduction
  134. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man
  135. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver
  136. EDITORIAL
  137. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
  138. FDG–PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis
  139. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S
  140. [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
  141. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature
  142. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation
  143. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
  144. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo
  145. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system
  146. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
  147. Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[18F]fluorobenzoate and application to 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography
  148. Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration
  149. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function
  150. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease
  151. Strategy for improved [11C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [11C]DAA1106
  152. Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels
  153. Endothelin Receptors
  154. Urotensin-II Receptor
  155. ET-B Endothelin Receptor
  156. ET-A Endothelin Receptor
  157. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation
  158. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis
  159. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system
  160. Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure
  161. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt
  162. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man
  163. International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function
  164. Triptan-induced contractile (5-HT1Breceptor) responses in human cerebral and coronary arteries: relationship to clinical effect
  165. Emerging roles of apelin in biology and medicine
  166. Regulation of vascular reactivity by established and emerging GPCRs
  167. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List
  168. Receptor Binding Techniques
  169. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells
  170. Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels
  171. Comparison of Endothelin-A and Endothelin-B Receptor Distribution Visualized by Radioligand Binding versus Immunocytochemical Localization using Subtype Selective Antisera
  172. Down-regulation of ETA Receptors in ETB Receptor-deficient Mice
  173. Endothelin Receptor Pharmacology and Function in the Mouse: Comparison with Rat and Man
  174. In Vivo Imaging of Cardiovascular Endothelin Receptors Using the Novel Radiolabelled Antagonist [18F]-SB209670 and Positron Emission Tomography (microPET)
  175. CRF2receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators
  176. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries
  177. Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats
  178. Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry
  179. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells
  180. Maternal Dexamethasone Increases Endothelin-1 Sensitivity and Endothelin A Receptor Expression in Ovine Foetal Placental Arteries
  181. Peptide and trace amine orphan receptors: prospects for new therapeutic targets
  182. Translating the human genome: renaissance of cardiovascular receptor pharmacology
  183. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system
  184. Life before birth: effects of cortisol on future cardiovascular and metabolic function*
  185. Is urotensin-II the new endothelin?
  186. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1
  187. Peptide Research Protocols
  188. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature
  189. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography
  190. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
  191. Of mice and men: advances in endothelin research and first antagonist gains FDA approval
  192. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors
  193. Radioligand binding reveals chymase as the predominant enzyme for mediating tissue conversion of angiotensin I in the normal human heart
  194. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1receptor antagonist losartan
  195. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteriesin vitro
  196. [125I-His9]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis
  197. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery
  198. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats
  199. The endothelin system in human saphenous vein graft disease
  200. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
  201. Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system
  202. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1
  203. Endothelin receptor antagonism in patients with chronic heart failure
  204. Urotensin II: fish neuropeptide catches orphan receptor
  205. Preface
  206. Cellular Expression of Isoforms of Endothelin-Converting Enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and Endothelin-Converting Enzyme-2
  207. Changes in ETA-, AT1- and AT2-Receptors in the Phenotypically Transformed Intimal Smooth Muscle Layer of Human Atherosclerotic Coronary Arteries
  208. Endothelin-A-Receptors in Human Aorta and Pulmonary Arteries are Downregulated in Patients With Cardiovascular Disease
  209. Expression and Characterization of the Human Endothelin-A-Receptor in Pichia pastoris
  210. No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease
  211. Novel Nitric Oxide Donors Reverse Endothelin-1-Mediated Constriction in Human Blood Vessels
  212. Syntheses of the First Endothelin-A- and -B-Selective Radioligands for Positron Emission Tomography
  213. Tissue-Specific Modulation of Endothelin Receptors in a Rat Model of Hypertension
  214. Evidence for Intracellular Endothelin-Converting Enzyme-2 Expression in Cultured Human Vascular Endothelial Cells
  215. Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain   Editorial Comment
  216. Endothelin receptor expression and pharmacology in human saphenous vein graft
  217. Secretory pathways in endothelin synthesis
  218. The therapeutic potential of PD156707 and related butenolide endothelin antagonists
  219. The haemodynamic effects of iodinated water soluble radiographic contrast media: a review
  220. Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707
  221. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease
  222. Human Endothelial Cell Storage Granules : A Novel Intracellular Site for Isoforms of the Endothelin-Converting Enzyme
  223. Endothelin receptor subtypes and their functional relevance in human small coronary arteries
  224. Evidence Using Immunoelectron Microscopy for Regulated and Constitutive Pathways in the Transport and Release of Endothelin
  225. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney
  226. Characterization of [125I]-PD164333, an ETAselective non-peptide radiolabelled antagonist, in normal and diseased human tissues
  227. Characterization of Site-Directed Antisera Against Endothelin-Converting Enzymes
  228. Endothelin Peptide and Converting Enzymes in Human Endothelium
  229. Endothelin-Converting Enzyme in the Human Vasculature: Evidence for Differential Conversion of Big Endothelin-3 by Endothelial and Smooth-Muscle Cells
  230. PD156707: A Potent Antagonist of Endothelin-1 in Human Diseased Coronary Arteries and Vein Grafts
  231. Relative Contribution of Endothelin A and Endothelin B Receptors to Vasoconstriction in Small Arteries from Human Heart and Brain
  232. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle
  233. Detection of Endothelin Receptors in Human Coronary Artery Vascular Smooth Muscle Cells But Not Endothelial Cells by Using Electron Microscope Autoradiography
  234. Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies
  235. Differential distribution of endothelin peptides and receptors in human adrenal gland
  236. Characterization of the binding of endothelin ETB selective ligands in human and rat heart
  237. Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and Aorta
  238. Selective downregulation of ETA receptor mRNA in renal transplant recipients on cyclosporin A revealed by quantitative RT-PCR
  239. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
  240. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments
  241. The endothelin system in the kidney
  242. Endothelin receptors in human coronary artery and aorta
  243. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart
  244. Localization of endothelin peptides in human kidney
  245. Endocrinology and paracrinology
  246. Radioligand Binding Assays: Theory and Practice
  247. Expression of Endothelin Peptides and Mrna in the Human Heart
  248. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells
  249. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm
  250. Endothelin expression in the uterus
  251. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro
  252. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
  253. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242
  254. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells
  255. Selectivity of [125I]-PD 151242 for human, rat and porcine endothelin ETA receptors in the heart
  256. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature
  257. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro
  258. Quantification of mRNA in Human Tissue Using Fluorescent Nested Reverse-Transcriptase Polymerase Chain Reaction
  259. Effects of Phosphoramidon and Pepstatin a on the Secretion of Endothelin-I and Big Endothelin-I by Human Umbilical Vein Endothelial Cells: Measurement by Two-Site Enzyme-Linked Immunosorbent Assays
  260. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats
  261. Davenport and Maguire reply
  262. Validation of mRNA Quantification in Human Kidney by a Novel Fluorescent Nested RT-PCR Method
  263. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?
  264. [125I]-PD 151242: a selective radioligand for human ETA receptors
  265. Isolation of Human Cardiac Endothelin Receptors by a Peptide-Receptor Mobility Shift Assay
  266. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney
  267. Alternatively Spliced mRNAs for Human Endothelin-2 and Their Tissue Distribution
  268. Endothelin: progress in pharmacology and physiology
  269. Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium
  270. Characterisation of Immunoreactive Endothelin in Human kidney by RP-HPLC and RIA
  271. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
  272. Quantitative autoradiography reveals higher densities of specific calcitonin-gene-related peptide receptors in small intramyocardial compared with large epicardial coronary arteries
  273. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle.
  274. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle
  275. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart
  276. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue
  277. Localization of immunoreactive endothelin and proendothelin in the human lung
  278. Endothelin-like immunoreactivity in human endometrium
  279. Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b
  280. Endothelins in reproduction
  281. Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta
  282. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues
  283. Binding sites for125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells
  284. Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography
  285. Mitogenic Effects of Vasoactive Peptides on Rat Vascular Smooth Muscle Cells
  286. Endothelin-1 stimulates prostaglandin F2α release from human endometrium
  287. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells
  288. Atrial natriuretic factor mRNA and binding sites in the adrenal gland
  289. Localisation off binding sites for iodinated endothelin and saraffotoxin peptides in mammalian tissues using quantitative receptor autoradiography
  290. Endothelin-1 mRNA is widely expressed in porcine and human tissues.
  291. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects
  292. Binding Sites for125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography
  293. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway—II. Differential localization of dopamine and cholecystokinin receptors
  294. Comparison between brain paste and polymer [125I]standards for quantitative receptor autoradiography
  295. Effect of the formamidine insecticide chordimeform on feeding and reproduction in the noctuid moth, Spodoptera littoralis (Boisduval)
  296. Quantitative receptor autoradiography
  297. Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect,Schistocerca gregaria, revealed by radioimmunoassay
  298. Octopamine distribution in the larvae and adults of two species of moth, Spodoptera littoralis and Manduca sexta
  299. The action of formamidines on octopamine receptors in the locust
  300. Toxicity of chlordimeform and amitraz to the egyptian cotton leafworm (Spodoptera littoralis) and the tobacco budworm (Heliothis virescens)
  301. Changes in haemolymph octopamine levels associated with food deprivation in the locust, Schistocerca gregaria
  302. Stress-induced changes in the octopamine levels of insect haemolymph
  303. Biogenic amines in the brain of the honeybee, Apis mellifera
  304. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  305. Imaging and Characterization of Radioligands for Positron Emission Tomography Using Quantitative Phosphor Imaging Autoradiography
  306. Immunocytochemical Localization of Receptors Using Light and Confocal Microscopy With Application to the Phenotypic Characterization of Knock-Out Mice
  307. Radioligand-Binding and Molecular-Imaging Techniques for the Quantitative Analysis of Established and Emerging Orphan Receptor Systems
  308. Apelins and the Apelin Receptor
  309. Radioligand Binding Assays and Quantitative Autoradiography of Endothelin Receptors
  310. Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay